Affiliations: [a]
Department of Biochemistry and Molecular Biology
| [b]
Department of Molecular Pharmacology and Experimental Therapeutics
| [c]
Paul F. Glenn Center for Biology of Aging Research at Mayo Clinic
| [d]
The Robert and Arlene Kogod Center on Aging
| [e]
Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA
Correspondence:
[*]
Correspondence to: Darren J. Baker, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA. Tel.: +1 507 538 4097; E-mail: baker.darren@mayo.edu.
Abstract: Background:The existence and contribution of microglia with senescent-like alterations in the pathogenesis of age-related neurodegenerative diseases like Alzheimer’s disease (AD) have been suggested in recent years. However, the identification of this distinct microglial population in vivo has proven challenging, largely due to overlaps in the inflammatory phenotype of activated and senescent microglia. Furthermore, attempts at recapitulating senescence in microglia in vitro are limited. Objective:To identify and characterize senescent microglia that occur in vivo in an animal model of neurodegeneration driven by pathologic tau. Methods:We analyzed the RNA expression patterns of individual microglia from normal mice and the pathogenic tau P301 S PS19 mouse model. We have previously demonstrated that p16-expressing senescent microglia occur in these mice when neurodegeneration has occurred. Results:Here we identify a subset of disease-associated microglia with senescent features, notably characterized by the expression of Ccl4. This signature overlaps with established markers of senescence from other cell types. Conclusion:Our characterization of senescent microglia can be used to better understand the role of senescent microglia in various age-related contexts, including whether clearance of senescent microglia represents a viable therapeutic option.
